First Human Dose Trial Investigating Safety, Tolerability and Pharmacokinetics of NNC0194-0499 in Male Subjects With Overweight or Obesity

Overview

This trial is conducted in The United States of America. The aim of this trial is to investigate Safety, Tolerability and Pharmacokinetics (the exposure of the trial drug in the body) of NNC0194-0499 in Male Subjects with Overweight or Obesity.

Full Title of Study: “A Randomised, Double-blinded, Single-dose, Dose-escalation, First Human Dose Trial Investigating Safety, Tolerability and Pharmacokinetics of NNC0194-0499 in Male Subjects With Overweight or Obesity”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: Double (Participant, Investigator)
  • Study Primary Completion Date: October 26, 2017

Interventions

  • Drug: NNC0194-0499
  • Drug: Placebo

Arms, Groups and Cohorts

  • Experimental: NNC0194-0499
    • Injected s.c. /subcutaneously (under the skin)
  • Placebo Comparator: Placebo
    • Injected s.c. /subcutaneously (under the skin)

Clinical Trial Outcome Measures

Primary Measures

  • Number of treatment-emergent adverse events (TEAEs)
    • Time Frame: From time of administration of NNC0194-0499 (day 1) to completion of the post-treatment period at follow-up (day 36)

Secondary Measures

  • The area under the NNC0194-0499 serum concentration-time curve after a single subcutaneous administration
    • Time Frame: From pre-dose (day 1) until the followup (day 36)
  • The maximum concentration of NNC0194-0499 in serum after a single subcutaneous administration
    • Time Frame: From pre-dose (day 1) until the followup (day 36)
  • The time to maximum concentration of NNC0194-0499 in serum after a single subcutaneous administration
    • Time Frame: From pre-dose (day 1) until the followup (day 36)

Participating in This Clinical Trial

Inclusion Criteria

  • Male, aged 22-55 years (both inclusive) at the time of signing informed consent – Body mass index (BMI) between 25.0 and 34.9 kg/m^2 (both inclusive). Overweight should be due to excess adipose tissue, as judged by the investigator Exclusion Criteria:

  • Any concomitant illness or disorder, which in the investigator's opinion might jeopardise the subject's safety or compliance with the protocol – Subjects aged above or equal to 40 years with an estimated 10-year atherosclerotic cardiovascular disease (ASCVD according to ACC/AHA (American College of Cardiology /American Heart Association) guideline) risk above or equal to 5% – Male subjects who are not sexually abstinent or surgically sterilised (vasectomy) and are sexually active with female partner(s) and who are not using a highly effective method of contraception (such as condom with spermicide) combined with a highly effective method of contraception for their non-pregnant female partner(s) (Pearl Index below 1%, such as implants, injectables, oral contraceptives, intrauterine devices, diaphragm or cervical cap+spermicide), and/or intend to donate sperm in the period from screening (visit 1) until 3 months following administration of the investigational medical product – Use of prescription or non-prescription medicinal products including herbal products and non-routine vitamins, within 2 weeks prior to screening, with the exception of occasional use of acetaminophen, ibuprofen or acetylsalicylic acid

Gender Eligibility: Male

Minimum Age: 22 Years

Maximum Age: 55 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Novo Nordisk A/S
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Global Clinical Registry (GCR,1452), Study Director, Novo Nordisk A/S

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.